Mobolaji Suleiman, MD
Geriatric Medicine · Kankakee, ILNPI 1184764086
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 95 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 14.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $559 and has fallen 73.4% since, to $148 in 2025.
Across 95 payments — averaging $18.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$262
- Boehringer Ingelheim$149
- GSK$114
- AbbVie$106
- Novartis$106
- Astellas Pharma US Inc$100
- plus $928 from 22 others
What the payments were for
- Food & beverage$1,765100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 17 | $262 |
| Boehringer Ingelheim | 7 | $149 |
| GSK | 6 | $114 |
| AbbVie | 5 | $106 |
| Novartis | 6 | $106 |
| Astellas Pharma US Inc | 5 | $100 |
| Medtronic | 2 | $100 |
| Pfizer | 5 | $95 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $83 |
| Dexcom, Inc. | 3 | $83 |
| Amgen | 5 | $75 |
| Johnson & Johnson | 3 | $70 |
| Lilly USA, LLC | 4 | $54 |
| Bayer | 3 | $46 |
| Merck | 2 | $35 |
| Almatica Pharma LLC | 2 | $35 |
| Renalytix AI, Inc. | 2 | $34 |
| AstraZeneca | 2 | $27 |
| Corium, LLC | 1 | $25 |
| Boston Scientific | 1 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Sanofi Pasteur Inc. | 1 | $20 |
| Viatris Specialty LLC | 1 | $18 |
| Greenwich Biosciences, Inc. | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Lundbeck LLC | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
How this compares
$1,765 in reported general payments places this provider in the 85th percentile of 147 geriatric medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 136 | $189,749 |
| JardianceEmpagliflozin | 162 | $179,747 |
| EliquisApixaban | 244 | $156,709 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 86 | $74,219 |
| MyrbetriqMirabegron | 45 | $51,406 |
| TrulicityDulaglutide | 32 | $43,816 |
| XareltoRivaroxaban | 56 | $38,778 |
| Abilify MaintenaAripiprazole | 12 | $36,206 |
| ZenpepLipase/Protease/Amylase | 11 | $23,735 |
| MounjaroTirzepatide | 21 | $22,074 |
| TradjentaLinagliptin | 28 | $19,747 |
| Memantine Hcl | 293 | $16,225 |
| Breo ElliptaFluticasone/Vilanterol | 30 | $14,633 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $12,863 |
| Atorvastatin Calcium | 1,109 | $11,040 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $149 | $208,868209 claims |
| Novo NordiskOzempic | $262 | $189,749136 claims |
| PfizerEliquis | $95 | $156,709244 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Anoro Ellipta, Incruse Ellipta | $114 | $110,102174 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $54 | $65,88953 claims |
| Astellas Pharma US IncMyrbetriq | $100 | $51,40645 claims |
| Johnson & JohnsonXarelto | $70 | $38,77856 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort, Brilinta | $27 | $34,05069 claims |
| MerckJanuvia | $35 | $10,19317 claims |
| NovartisEntresto | $106 | $9,31131 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 147 geriatric medicine providers in Illinois.
Other geriatric medicine in Kankakee
- Michael LimArlington Heights$29K
- Hima AtluriDecatur$21K
- Carlos Mella-PicelChicago$9K
- Rekha SharmaHazel Crest$8K
- Beata StykaPalos Heights$6K
- Azeem AhsanCrest Hill$6K
- Adeela CheemaChicago$5K
- Alex SanchezElgin$5K
- Seong ChinGlenview$4K
- Thomas CozziArlington Heights$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.